Reduce regulatory requirements for biosimilar drug approval to increase market competition and lower prescription costs.
One policy goal, tracked across every bill that has carried it.
What’s happening with Biosimilar Red Tape Elimination Act?
The Biosimilar Red Tape Elimination Act remains stalled in the House Committee on Energy and Commerce as of June 18, 2026. The committee members must hold a vote to move the bill forward, but most legislation never receives this step. The bill has seen no action since September 18, 2025.
Updated July 9, 2026 · Generated by AI. Always verify with official sources.
Where it stands
Now carried by Biosimilar Red Tape Elimination Act (H.R. 5526 (119th)) →
Legislative Progress
No action since September 2025
Next up: A house committee · Nothing moves until they act.
How we got here
Every bill that has carried this goal, oldest first.
Died with Congress · Jan 3, 2025
Died when the 118th Congress ended without final passage. Bills must be reintroduced under a new number to be revived.
Reintroduced · Jan 3, 2025
Reintroduced from S. 2305 (118th), which died when its Congress ended.
S. 2305 (118th) →
Vehicles
Who’s behind it
August Pfluger (R-TX)Wrote and sponsored the current bill.
